

Lanfranco Pellesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9162336/publications.pdf>

Version: 2024-02-01

29
papers

574
citations

686830

13
h-index

642321

23
g-index

31
all docs

31
docs citations

31
times ranked

723
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?. <i>Headache</i> , 2020, 60, 1056-1065.	1.8	58
2	Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 534-547.	0.8	56
3	Triptans and CGRP blockade – impact on the cranial vasculature. <i>Journal of Headache and Pain</i> , 2017, 18, 103.	2.5	50
4	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. <i>Journal of Headache and Pain</i> , 2016, 17, 48.	2.5	49
5	Migraine and cluster headache – the common link. <i>Journal of Headache and Pain</i> , 2018, 19, 89.	2.5	44
6	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , 2017, 8, 586.	1.1	42
7	Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches. <i>JAMA Network Open</i> , 2021, 4, e2118543.	2.8	38
8	Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. <i>Journal of Headache and Pain</i> , 2017, 18, 71.	2.5	34
9	Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. <i>Pharmacological Research</i> , 2018, 133, 65-76.	3.1	30
10	Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. <i>Cephalalgia</i> , 2020, 40, 1212-1223.	1.8	30
11	Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH) – a pilot study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1427-1436.	0.8	27
12	Quality indicators in headache care: an implementation study in six Italian specialist-care centres. <i>Journal of Headache and Pain</i> , 2017, 18, 55.	2.5	19
13	Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 189-198.	1.5	19
14	Nabilone administration in refractory chronic diarrhea: a case series. <i>BMC Gastroenterology</i> , 2019, 19, 105.	0.8	13
15	Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare Network. <i>Cephalalgia</i> , 2018, 38, 1429-1441.	1.8	9
16	PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. <i>Cephalalgia</i> , 2022, 42, 687-695.	1.8	8
17	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. <i>Journal of Headache and Pain</i> , 2019, 20, 15.	2.5	7
18	Nummular headache: a gender-oriented perspective on a case series from the RegistRare Network. <i>Neurological Sciences</i> , 2020, 41, 583-589.	0.9	7

#	ARTICLE	IF	CITATIONS
19	A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 467-474.	1.0	7
20	Clinical Evidence of Cannabinoids in Migraine: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1479.	1.0	7
21	Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. <i>Cephalalgia</i> , 2020, 40, 1070-1078.	1.8	6
22	Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study. <i>Frontiers in Neurology</i> , 2022, 13, 871176.	1.1	6
23	Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medicationâ€œoveruse headache. <i>BMC Neurology</i> , 2019, 19, 239.	0.8	3
24	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. <i>Drug, Healthcare and Patient Safety</i> , 2021, Volume 13, 233-240.	1.0	3
25	<p>Reducing Episodic Cluster Headaches: Focus on Galcanezumab</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 1591-1599.	0.8	2
26	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , 2018, 9, .	1.1	0
27	Response to: â€œDrugs for treatment for alcohol use disorders expose to interactions with others â€ for little benefit if anyâ€;. <i>Pharmacological Research</i> , 2018, 134, 220.	3.1	0
28	SAT0285â€œ...EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS. , 2019, , .		0
29	Greater Occipital Nerve Block with Local Anesthetics and Corticosteroids in Treatment-Resistant Chronic Migraine. <i>Headache Medicine</i> , 0, , 160-167.	0.1	0